Almac Group, a global CDMO, reported that global workforce has reached 7,000 people, a total growth of over 1,000 employees in the last 18 months.

In a statement, the company said that the rise, aligned with the current capital investment program, means Almac is well on its way to delivering on the significant expansion plans that were first announced in November 2021.

The company also announced its financial results for year ending September 30, 2022. The company recorded a $134 million (14%) rise in revenue to nearly $1.1 billion in 2022. Pre-tax profits were recorded at $124 million, a 20% increase for the same period the previous year. 

Alan Armstrong, Almac Group Chairman and CEO said: “Today’s announcement is a welcome continuation of growth for Almac Group, and I would like to thank all within the organization for playing their part. We are committed to reinvesting all our profits in the business, this success will play a vital part in our continued growth, expansion, and increase in our employee numbers.

Armstrong added: “Almac is dedicated to ensuring we remain a global leader in our industry, giving our clients and ultimately patients across the world the best possible offering. We continue to play our part as a valued and trusted member of the communities in which we operate.”

During this financial year, the group was involved in the development of hundreds of life-saving drugs spanning more than 20 therapeutic areas including oncology, cardiology, immunology, gene therapy and neurology.